Sulbactam+Cefoperazone in Treatment of Complicated Urinary Tract Infections

Abstract

The clinical efficacy and safety of sulbactam+cefoperazone combination was evaluated 30 patients suffering from serious urinary tract infection, complicated with urinary tract obstruction. All of the patients who were operating lists, with proven urinary tract infection were given a total daily dose of 2 gr sulbactam combined with 2 gr cefoperazone. Drug administration continued for jive days intravenously twice daily. A 90 percent bacteriological eradication of the isolates was achieved and no significant side effects. Results of the bacteriological studies together with the clinical course of patients confirmed excellent therapeutic efficacy and safety of this drug.

Keywords

• urinary tract infections,sulbactam,cefaperazone

Komplike Üriner Sistem İnfeksiyonlarinin Tedavisinde Sulbaktam+Sefoperazon

Öz

Sulbaktam + Sefoperazon kombinasyonunun etkinliği ve klinik güvenilirliği, üriner sistem obstrüksiyonu ile komplike üriner sistem infeksiyonu bulunan 30 hastada denendi. Hastalann tamamına operasyondan bir gün önce 2 gr sulbaktamla kombine 2 gr sefoperazon total günlük doz olarak başandı. Tedaviye daha sonra beş gün süre ile aynı doz günde iki defada İV yolla verilerek devam edildi. İzole edilen bakterilerde %90 oranında eradikasyon sağlanırken önemli bir yan etkiye rastlanmadı. Sonuç olarak bakteriyolojik ve klinik veriler bu kombinasyonun üriner sistem infeksiyonlarında etkili ve güvenilir olduğunu gösterdi.

Anahtar Kelimeler

• Üriner sistem infeksiyonu,sulbaktam,sefoperazon

Kaynakça

1. Kobayashi S, Arai S, Hayashi S, Sakaguchi T. In vitro effects of beta-lactams combined with beta-lactamase inhibitors against methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy. 1989:33(3);331-335. doi: ı0.ıı28/AAC.33.3.33ı
2. Williams JD. Importance of beta-lactamase and clinical implications of their inhibitors. Drugs. 1988;35:3-11.
3. Kawada Y. The significance of the combination of sulbactam and cefoperazone in the treatment of complicated urinary infections. Sulbactam: An Advance in Overcoming Bacterial Resistance. Science Press, Seul. 1986;66-70.
4. Kawada Y, Nishiura T. Clinical evaluation of cefoperazone/sulbactam in the surgical field. Sixth international Cefoperazone Symposium, Tokyo, 1982; p.69.
5. Gutmann L, Williamson R, Kitzis MD, Acar JF. Synergism and antagonism in double beta-lactam antibiotic combinations. The American journal of medicine. 1986;80(5C):21-29.
6. Kunii O. Clinical evaluation of sulbactam I cefoperazone in the field of internal medicine. Sixth International Cefoperazone Symposium, Tokyo.1982; p.61.
7. Uneo K. Bacteriological studies of sulbactam / cefoperazone. Sulbactam: An Advance in Overcaming Bacterial Resistance, Scince Press, 1986;25-27.
8. Fu KP, Neu J-JC. Synergistic activity of cefoperazone in combination with beta-lactamase inhibitors. J Antimicrob Chemother. 1981;7(3): 287-292. doi: ı0.ı093/jac/7.3.287

9. Sözer H. Urogenital infeksiyonlarda sefoperazon/ sulbaktam kombinasyonu. İlaç Tedavi Dergisi. 1994;7:32-33.
10. Yaman LS, Kandilci S, Gemalmaz H. Nonkomplike genitoüriner infeksiyonlann tedavisinde Sulperazone (sefoperazon + sulbaktam). İlaç ve Tedavi Dergisi. 1994;7:29-31.
11. Özyurt M, Yavaşcaoğlu İ, Şimşek Ü, Oktay B, Kavrama İ. Clinical experience with sulbactam / sefoperazone in complicated urinary tract infections. İlaç ve Tedavi Dergisi. 1994;7:34-36.
12. Reitberg DP, Marble DA, Schultz RW, et al. Pharmacokinetics of cefoperazone and sulbactam coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis. Antimicrob Agents Che Mother. 1988; 32: 503-509.